Kristi Rosa on Muck Rack

Kristi Rosa

Verified
Freehold
As seen in: OncLive, NewsBreak, HCP Live, Contagion Live, American Journal of Managed Care, Pharmacy Times, ONCOLOGY journal, CURE Magazine, Contemporary OB/GYN, Contemporary Pediatrics, Dermatology Times and
associate editorial director of @OncLive. bibliophile. foodie. cat mom. opinions are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kristi

Contact Kristi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ASCENT-04 Data Yields Longer PFS2 in Previously Untreated Metastatic TNBC

|
By Praful Ravi, Kristi Rosa , Ariana Pelosci 
| ONCOLOGY journal
Results from the phase 3 ASCENT-04 trial (NCT05382286) showed first-line sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) incurred a longer progression-free survival (PFS) after next line of treatment (PFS2) compared with chemotherapy plus pembrolizumab for patients with previously untreated, PD-L1–positive locally advanced unresectable or metastatic triple-negative (mTNBC).
Open in Who Shared Issue with article?

Pembrolizumab Demonstrates Durable EFS and OS Benefit in High-Risk TNBC

|
By Kristi Rosa , Ashling Wahner , Russ Conroy
| ONCOLOGY journal
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Peter Schmid, MD, PhD, of the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK, presented final analysis results from the phase 3 KEYNOTE-522 trial (NCT03036488) evaluating perioperative pembrolizumab (Keytruda) plus chemotherapy in patients with high-risk, early-stage triple-negative breast cancer (TNBC).1 At the final analysis, event-free survival (EFS) events...
Open in Who Shared Issue with article?

Post-Surgery Nivolumab Shows No DFS Improvement in EGFR/ALK-Negative NSCLC

|
By Kristi Rosa , Ashling Wahner , Russ Conroy
| ONCOLOGY journal
Administering nivolumab (Opdivo) after standard-of-care adjuvant therapy did not improve disease-free survival (DFS) compared with best supportive care among patients with resected lung adenocarcinoma without sensitizing EGFR and ALK alterations, according to data from the phase 3 ECOG-ACRIN EA5142 or ALCHEMIST trial (NCT02595944) presented at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO) and simultaneously published in JAMA.1,2 Data showed a median DFS of 71.3 months...
Open in Who Shared Issue with article?
See all 3,220 licensed articles (3,324 Total)

Actions

Share this page

Get in touch with Kristi

Contact Kristi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified